Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Shares Issued (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Shares Issued for 6 consecutive years, with $73000.0 as the latest value for Q4 2025.

  • Quarterly Shares Issued rose 392.0% to $73000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $73000.0 through Dec 2025, up 14.06% year-over-year, with the annual reading at $73000.0 for FY2025, 14.06% up from the prior year.
  • Shares Issued for Q4 2025 was $73000.0 at Lexicon Pharmaceuticals, up from -$25000.0 in the prior quarter.
  • The five-year high for Shares Issued was $139.0 million in Q2 2023, with the low at -$25000.0 in Q4 2024.
  • Average Shares Issued over 3 years is $46.3 million, with a median of $80500.0 recorded in 2024.
  • The sharpest move saw Shares Issued crashed 100.0% in 2024, then soared 392.0% in 2025.
  • Over 3 years, Shares Issued stood at $138.5 million in 2023, then plummeted by 100.02% to -$25000.0 in 2024, then skyrocketed by 392.0% to $73000.0 in 2025.
  • According to Business Quant data, Shares Issued over the past three periods came in at $73000.0, -$25000.0, and $1000.0 for Q4 2025, Q4 2024, and Q2 2024 respectively.